Back to Search
Start Over
Vaccine design and delivery approaches for COVID-19
- Source :
- International Immunopharmacology
- Publication Year :
- 2021
-
Abstract
- COVID-19 is still a deadly disease that remains yet a major challenge for humans. In recent times, many large pharmaceutical and non-pharmaceutical companies have invested a lot of time and cost in fighting this disease. In this regard, today's scientific knowledge shows that designing and producing an effective vaccine is the best possible way to diminish the disease burden and dissemination or even eradicate the disease. Due to the urgent need, many vaccines are now available earlier than scheduled. New technologies have also helped to produce much more effective vaccines, although the potential side effects must be taken into account. Thus, in this review, the types of vaccines and vaccine designs made against COVID-19, the vaccination programs, as well as the delivery methods and molecules that have been used to deliver some vaccines that need a carrier will be described.
- Subjects :
- Vaccine delivery
SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus-2
APC, Antigen-Presenting Cell
S.C., Subcutaneous
MERS, Middle East Respiratory Syndrome
RSV, Respiratory Syncytial Virus
Disease
SAGE, Strategic Advisory Group of Experts on Immunization
Health Services Accessibility
Delivery methods
Immunology and Allergy
Drug Approval
Vaccine design
CDC, Centers for Disease Control and Prevention
PAMP, Pathogen-Associated Molecular Pattern
LNP, Lipid Nanoparticles
Vaccination
LMH, Live Modified Horsepox
Chimpanzee Adenoviral Vector 1, ChAdOx1
Ad, Adenovirus
GMV, Genetically Modified Viruses
TLR, Toll-Like Receptor
EUA, Emergency Use Authorization
ACE2, Angiotensin Converting Enzyme 2, Coalition for Epidemic Preparedness Innovations
medicine.medical_specialty
2019-20 coronavirus outbreak
COVID-19 Vaccines
Coronavirus disease 2019 (COVID-19)
I.M., Intramuscular
Emerging technologies
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
VRP, Virion Replicon Particle
Immunology
ASHP, American Society of Health-System Pharmacists
Article
SDG 3 - Good Health and Well-being
medicine
Humans
Intensive care medicine
LAV, Live-Attenuated Virus
Disease burden
Pharmacology
VLP, Virus-Like Particle
SARS-CoV-2
COVID-19, Coronavirus Disease-19
business.industry
COVID-19
RBD, Receptor Binding Domain
PRR, Pattern Recognition Receptors
MVA, Modified Vaccinia Ankara
VEE, Venezuelan Equine Encephalitis
Nanoparticles
business
Vaccine
WCA, Whole-Cell Antigen
Subjects
Details
- Language :
- English
- ISSN :
- 15675769
- Volume :
- 100
- Database :
- OpenAIRE
- Journal :
- International Immunopharmacology
- Accession number :
- edsair.doi.dedup.....97c9be9438e08539da23317f11ef7827